Skip to main content
. 2021 Aug 10;14:3797–3808. doi: 10.2147/JIR.S316078

Figure 3.

Figure 3

(A) Concentrations of endogenous arginine-related pathway metabolites in patients after acute myocardial infarction (AMI) who developed major adverse cardiovascular events (MACE), compared to those who did not during the median follow-up of 3.5 years. (B) ROC curve showing the predictive value of symmetric dimethylarginine (SDMA) for the MACE curve.